AbbVie: Dominating Immunology While Building Oncology Upside

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...
Seeking Alpha

AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq

Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 results, which, according to BNP Paribas, were driven by its older blockbuster ...
FiercePharma

AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...
Yahoo Finance

AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AbbVie (NYSE:ABBV) has agreed to acquire Capstan ...